(Q91123540)

English

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

scientific article published on 16 January 2019

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

recurrent malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

author name string

Maria J Disselhorst

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Josine Quispel-Janssen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Ferry Lalezari

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Kim Monkhorst

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Jeltje F de Vries

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Vincent van der Noort

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Emmy Harms

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Sjaak Burgers

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Paul Baas

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

publication date

16 January 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

260-270

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of shortened infusion times for combined ipilimumab and nivolumab.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930420-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(18)30420-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660511%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q91123540&oldid=1531347552"